Times Have Changed: FDA Ends ESA REMS Ahead Of First Biosimilars
FDA is ending one of the landmark drug safety programs from the REMS era, announcing it has released Amgen from its mandatory obligations for the erythropoiesis-stimulating agent (ESA) class. The decision comes just ahead of the likely approval of the first biosimilar application in the class.
You may also be interested in...
FDA commissioner-nominee Scott Gottlieb is expected to steer clear of pricing issues at the agency, despite his reputation as a thought leader on the issue.
Democrats test US FDA commissioner nominee's willingness to defend agency independence during confirmation hearing and probe potential conflicts of interest.
At least five biosimilars could gain US licensure in the coming year on first-cycle review, including subsequent competitors to Remicade and Humira; however, patent litigation is expected to increase and will continue to slow the march of products from FDA approval to commercialization.